Total compensation: $8,331,159 for the year ended April 30
Salary: $1,459,080
Non-equity incentive pay: $4,682,931
Other compensation: $52,614
Value realized on vesting shares: $2,136,534
New stock options: 221,765
Total fiscal 2014 shareholder return: 28.6 percent
Note: Ishrak took home $8.3 million in total compensation, a 33 percent increase over the amount he took home the previous year.
Ishrak's base salary rose 4 percent last year, but the biggest part of his total compensation increase was a bonus that went from $2.4 million to $4.7 million as the company slightly exceeded the overall targeted revenue, earnings per share and cash flow performance goals.
There is little mention of the pending Covidien deal in the preliminary proxy other than Covidien is currently in Medtronic's peer group. The deal was announced after the company's fiscal year closed, and any bonuses associated with the acquisition may be listed in next year's proxy.
Shareholders at last year's annual meeting gave the big medical device company's "say-on-pay'' proposal 97 percent approval.
Patrick Kennedy
Trust is at the core of a long-term financial planning relationship.
